The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine marstacimab (Hympavzi) to prevent or reduce bleeding in patients 12 years of...
The U.S. Food and Drug Administration (USFDA) approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of...
Prophylactic, or preventive, treatment with factor VIII (FVIII) replacement therapy for four years reduced annual bleeding rates by 91% for...
1 Introduction Hemophilia is an X-linked recessive disorder caused by the deficiency in coagulation factor VIII (FVIII; hemophilia A) or...
Anette von Drygalski, MD, PharmD, is the director of the Center for Bleeding and Clotting Disorders at UC San Diego...
Brazilian hemophilia A patients who are 19 or older had significantly higher median care costs per patient per year than...
